About this trial
A medical professional trained in the procedure and use of the device will conduct the vibroacoustic therapy session. He will also take blood samples.
In the control group, patients will undergo vibroacoustic pulmonary therapy in the "Pneumonia" mode, and in the control group, in the "Prevention" mode. Vibroacoustic pulmonary therapy will be conducted over a period of 5 days. A similar algorithm of actions is planned for both groups. VALT sessions will be conducted 4-6 times a day for 5 minutes in combination with treatment according to the protocol for the use of "Vibroacoustic Therapy" of the lungs of the Ministry of Health of the Republic of Kazakhstan. The device's emitters will be applied to the affected areas of the lungs. Since the device has long cords for the emitters and is portable, it is not difficult to change the patient's position and does not require their active participation, which is important for patients on ventilators and with limited mobility.
Eligibility criteria
Qualifiers
respiratory failure;
hip fracture;
Injury Severity Score no higher than 8 points.
Disqualifiers
terminal condition of the patient;
shock;
paradoxical pathological breathing;
hypertensive crisis;
Trial design
Treatments tested in this trial
- Vibrolung